South Shore Neurologic Associates Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01328379
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates, P.C.

Active Ingredients

Drugs in Phase 3 Trials (1)

dalfampridine (ampyra) (1 trial)

Drugs in Phase 2 Trials (1)

ibudilast (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Motor Neuron Disease (Phase 2)

Multiple Sclerosis (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2